Epsilon Molecular Engineering. Inc (EME.Inc) is a Biotech startup from Saitama University, founded in 2016. Our technology is based on evolutionary molecular engineering from Naoto Nemoto lab (Saitama University), and we have been approaching the world with the technology of next-generation antibodies, VHH antibodies.
“The Month” is our high-throughput screening platform that is the combination of cDNA display and PharmaLogical™ Library, and it allows us to obtain functional and high quality VHH clones in 30 business days. cDNA display is a protein display method that has high stability and handles a larger size (1013-14) of the library than other display methods such as Phage display. PharmaLogical™ Library is a well-structured, synthetic VHH library that is druggable, and is based on X-ray crystallography of antigen-VHH complexes.
We contribute to our world, society, and people’s lives with next-generation antibodies, VHH antibodies. VHH antibodies have the binding potential to access difficult targets which conventional antibodies cannot, and it can be utilized for various fields such as therapeutics, diagnostics, and imaging.
(maximum measured value)
- Designed High DiverseLibrary
We have a unique library which has a huge library size; 1013-14. We isolate clones from this library so that it allows obtaining many clones which have unique amino acid sequences.
- Advanced high-throughput screeningOur high-throughput screening allows you to obtain unique hit clones which are functional and very stable in 30 business days. 30 business days is a much shorter timeline than general screening methods so that you can save your cost and time.
- Cruelty free for antibody discovery
Since our screening method only requires in vitro experiments, we do not require animal experiments such as blood collection and injecting antibodies to animals.
- Joint research and Alliance
- Licensing out of pipeline
- Each licensing business
- Commissioned business
Innovative biopharmaceuticals discovery company for creating new modalities
We own unique VHH library;PharmaLogical ®Libraryand unique technology; cDNA display. Also, we have unique platform “The Month” which is the combination of PharmaLogical ®Library and cDNA display. We have been utilizing this platform for joint research with pharmaceutical companiesand approachingdrug discovery.We also have other business models (1)licensing out our pipelinewhich utilizes PharmaLogical ® VHHand (2) licensingbusiness for our unique technologies such as PharmaLogical ®Libraryand cDNA display.
“The Month”The Cutting-Edge Discovery Platform which is the combination of cDNA display and PharmaLogical® Library. The unique point of this platform is obtaining druggable candidates in only 30 business days.
cDNA DisplayOur protein display method which is genotype/phenotype linking systems. cDNA display has high stability and it handles a huge VHH antibody library.
PharmaLogical ® LibraryA well-structured, synthetic VHH antibody library that is druggable, and is based on X-ray crystallography of antigen-VHH complexes.
Design PlatformMolecular engineering
PipelineUtilized our advanced technologies for tackling Unmet medical needs.
EVENT: EME will join Antibody Engineering & Therapeutics 2023 as an associate sponsor.
Northwestern University experts published to Nature “Mega-scale experimental analysis of protein folding stability in biology and design” in July 2023. The research team utilized EME’s cnvK linker for development of cDNA display proteolysis method.
【Overseas Event】EME will join Bio international Convention 2023
- 2024.02.21Press Release
EME and ONO Announce Collaboration Agreement on Creating Novel VHH antibody drug discovery
- 2023.07.28Press Release
EME entered into a comprehensive collaboration agreement with Kao for Multiple Infectious Diseases with Utilizing PharmaLogical™ VHH.
- 2023.02.07Press Release
EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical® VHH to address an unmet medical need in Obstetrics and Gynecology